Compare XTNT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6M | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | XTNT | KPTI |
|---|---|---|
| Price | $0.83 | $7.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 231.4K | 199.6K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $133,083,000.00 | ★ $142,530,000.00 |
| Revenue This Year | $15.95 | $3.82 |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | $68.87 | ★ N/A |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $0.34 | $3.51 |
| 52 Week High | $0.95 | $12.45 |
| Indicator | XTNT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 63.71 | 60.74 |
| Support Level | $0.70 | $5.99 |
| Resistance Level | $0.81 | $7.48 |
| Average True Range (ATR) | 0.06 | 0.53 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 81.42 | 72.48 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.